Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial

Authors:

Top Cited Papers
Open Access
Abstract
Cystectomy is a standard treatment for muscle-invasive bladder cancer (MIBC), but it is life-altering. We initiated a phase 2 study in which patients with MIBC received four cycles of gemcitabine, cisplatin, plus nivolumab followed by clinical restaging. Patients achieving a clinical complete response (cCR) could proceed without cystectomy. The co-primary objectives were to assess the cCR rate and the positive predictive value of cCR for a composite outcome: 2-year metastasis-free survival in patients forgoing immediate cystectomy or ATM,RB1,FANCCandERCC2) or increased tumor mutational burden did not improve the positive predictive value of cCR. Exploratory analyses of peripheral blood mass cytometry and soluble protein analytes demonstrated an association between the baseline and on-treatment immune contexture with clinical outcomes. Stringently defined cCR after gemcitabine, cisplatin, plus nivolumab facilitated bladder sparing and warrants further study. ClinicalTrials.gov identifier:NCT03558087.
Funding Information
  • V Foundation for Cancer Research (T2019-011)
  • Bristol-Myers Squibb (CA209-9AU, CA209-9AU, CA209-9AU, CA209-9AU, CA209-9AU, CA209-9AU, CA209-9AU, CA209-9AU, CA209-9AU, CA209-9AU, CA209-9AU, CA209-9AU, CA209-9AU, CA209-9AU, CA209-9AU)
  • U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA196521, U24CA224319)
  • Foundation for the National Institutes of Health (FNIH)/Partnership for Accelerating Cancer Therapies

This publication has 50 references indexed in Scilit: